论文部分内容阅读
新辅助化疗联合中间性肿瘤细胞减灭术给不适合初次肿瘤细胞减灭术的晚期卵巢癌患者带来新的希望,但术前筛选恰当的患者予以新辅助化疗是妇科肿瘤医生的一大挑战。低白蛋白血症是卵巢癌初次肿瘤细胞减灭术术后并发症高发的独立危险因素之一。本文将就低白蛋白血症对卵巢癌新辅助化疗加中间性肿瘤细胞减灭术(neoadjuvant chemotherapy&interval debulking surgery,NACT-IDS)治疗模式的影响进行综述。
Neoadjuvant chemotherapy combined with cytoreductive surgery provides new hope for patients with advanced ovarian cancer who are not suitable for initial cytoreductive surgery, but neoadjuvant chemotherapy in patients with appropriate screening preoperatively is a major challenge for gynecologic oncologists . Hypoproteinemia is one of the independent risk factors for the high incidence of postoperative complications of primary cytoreductive ovarian cancer. This article reviews the impact of hypoalbuminemia on the neoadjuvant chemotherapy and interval debulking surgery (NACT-IDS) model of ovarian cancer.